ACAD vs SO · P/E 15, rev $957.8M vs P/E 22, rev $29.55B
ACADIA Pharmaceuticals Inc (ACAD) versus Southern Company (SO) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Southern Company (SO) is a utilities - regulated electric company listed on US.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported SO revenue for 2025-12-31 was $29.55B. Net income was $4.34B. Revenue was up 10.6% from 2024-12-31 to 2025-12-31. SO currently screens at market cap $101.55B and trailing P/E 22.1.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. SO currently screens at market cap $101.55B and trailing P/E 22.1.
Not investment advice. Open the ACAD and SO stock pages for the full models.
Not investment advice.